Business Description
Windtree Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US97382D6004
Total Employee Number:
14Description
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.02 | |||||
Equity-to-Asset | -0.73 | |||||
Debt-to-Equity | -1.11 | |||||
Debt-to-EBITDA | -0.3 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 92.9 | |||||
3-Year EPS without NRI Growth Rate | 82.7 | |||||
3-Year FCF Growth Rate | 77 | |||||
3-Year Book Growth Rate | -90.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 88.48 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.38 | |||||
9-Day RSI | 41.2 | |||||
14-Day RSI | 34.01 | |||||
3-1 Month Momentum % | -98.75 | |||||
6-1 Month Momentum % | -98.02 | |||||
12-1 Month Momentum % | -99.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.33 | |||||
Quick Ratio | 0.33 | |||||
Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -535 | |||||
Shareholder Yield % | 1392.86 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -1198.07 | |||||
ROA % | -150.47 | |||||
ROIC % | -49.04 | |||||
3-Year ROIIC % | -12.85 | |||||
ROC (Joel Greenblatt) % | -4196.49 | |||||
ROCE % | -313.25 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.3 | |||||
EV-to-EBITDA | -0.3 | |||||
EV-to-Forward-Revenue | 0.26 | |||||
EV-to-FCF | -0.84 | |||||
Earnings Yield (Greenblatt) % | -333.33 | |||||
FCF Yield % | -151210 |
GF Valueâ„¢
Windtree Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Windtree Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 149 days | ||
| Third quarter earnings results for 2026 | 2026-11-19 | In 64 days | ||
| Second quarter earnings results for 2026 | 2026-09-16 | 0.00 (+50.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 0.06 (+1.55%) | ||
| Second quarter earnings results for 2025 | 2025-08-19 | 0.49 (-2.49%) | ||
| First quarter earnings results for 2025 | 2025-05-16 | 0.83 (-3.49%) | ||
| Annual report for 2024 | 2025-04-15 | 1.36 (+3.82%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-15 | 1.36 (+3.82%) | ||
| 0.02:1 Stock Split | 2025-02-21 | 4.80 (-4.00%) | ||
| Third quarter earnings results for 2024 | 2024-11-27 | 28.18 (+0.64%) |
Show
Entries
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers